Performance characteristics of ThyroSeq, ThyGeNEXT/ThyraMIR, and Afirma molecular platforms in evaluation of 1252 cytologically-indeterminate thyroid nodules
The ThyroSeq, ThyGeNEXT/ThyraMIR, and Afirma molecular platforms demonstrate similar efficacy in ruling out malignancy in our cohort's cytologically indeterminate thyroid nodules, with sensitivities of 87.5%, 66.7%, and 73.1%, respectively, and negative predictive values of 80.0%, 70.0%, and 66.0%, respectively. Overall performance characteristics of these molecular platforms in our study are inferior to some previously published studies.
Authors
- Swikrity U Baskota (ORCID: https://orcid.org/0009-0009-6362-1043)
- Niyati Desai (ORCID: https://orcid.org/0000-0001-6610-8637)
- Marie C. Smithgall (ORCID: https://orcid.org/0000-0001-6706-0700)
- Adela Cimic (ORCID: https://orcid.org/0000-0001-7593-1182)
- Courtney Connelly (ORCID: https://orcid.org/0009-0007-0300-0697)
Institutions
- Columbia University Irving Medical Center (US)
- University of California System (US)
- UC Davis Health (US)
Publication Details
- Journal
- Journal of the American Society of Cytopathology
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.jasc.2025.04.003
- Citations
- 4
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.18